E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 9/21/2006 in the Prospect News Biotech Daily.

S&P puts Merck on watch

Standard & Poor's said it placed its BBB+/A-2 corporate credit ratings on Merck KGaA on CreditWatch with negative implications, following its unexpected takeover of Serono SA for a €10.6 billion.

At the same time, the long-term A- corporate credit rating on Serono was placed on CreditWatch with negative implications, the agency said.

S&P added that the rating action mainly reflects the deterioration in the combined group's financial profile, adding that while the financing structure includes an equity share of between €2 billion and €2.5 billion, the acquisition entails a significant portion of debt funding, resulting in materially higher leverage than is currently the case.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.